Search
Last updated: May 18.2018
https://www.alk.net/our-company/privacy
Get answers about privacyALK PrivacyWe have recently added some further detail in our Privacy Statement, making it easier for you to understand what data we collect, how we use it and your rights to manage that information.
L...
Last updated: February 18.2019
https://www.alk.net/how-apply
How to apply
Research proposal form
Data sharing agreement
To apply for access to clinical trial data, please complete and submit the research proposal form including CVs and a statis...
Last updated: December 14.2018
https://www.alk.net/review-application
Review of application
Scientific Review Board Charter
Access to data may be provided following review of the application by a scientific review board including independent academic scientists an...
Last updated: November 28.2018
https://www.alk.net/status-applications
Status of applicationsNo applications have been received
Last updated: February 22.2019
https://www.alk.net/synopses
SynopsesALK sponsored clinical trial protocol information and results, regardless of outcome, are disclosed in publicly accessible clinical trial registries, for example EudraCT (clinicaltrialsregister.eu), clinicaltrials.gov or on this page....
Last updated: February 8.2019
https://www.alk.net/allergy-solutions-life
Updated ALK branding: Allergy solutions for lifeWe are a year into our transformation strategy, and ALK’s tagline and other branding materials have been updated to reflect our company’s expanded focus on reaching many more people with allerg...
Last updated: May 2.2019
https://www.alk.net/henning-lowenstein-research-award-2019
The ARIA-EUFOREA Henning Løwenstein Research Award 2019The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.
Ca...
Last updated: December 5.2017
https://www.alk.net/strategy-usa
Growth strategy: Establish and succeed in North America Priority 1: North America is the world's largest allergy market, with over 50 million allergy sufferers, and it offers ALK the greatest medium-term growth potential. For example, t...
Last updated: December 5.2017
https://www.alk.net/strategy-complete-tablet-portfolio
Growth strategy: Complete the tablet portfolio for all relevant agesPriority 2: ALK is committed to offering a full portfolio of tablets for all relevant ages, covering the five most common global respiratory allergies....
Last updated: December 5.2017
https://www.alk.net/patient-engagement
Growth strategy: Patient engagement systems and adjacent businessPriority 3: ALK will establish a new commercial consumer care division to drive digital patient engagement with the ultimate aim of creating new value from ALK's expanded...